PubRank

Ettore C degli Uberti

Author PubWeight™ 31.43‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 miR-15a and miR-16-1 down-regulation in pituitary adenomas. J Cell Physiol 2005 1.93
2 Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. Eur J Endocrinol 2008 1.65
3 Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma. Thyroid 2005 1.39
4 Predictive value of circulating insulin-like growth factor I levels in ischemic stroke outcome. J Clin Endocrinol Metab 2006 1.15
5 BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur J Endocrinol 2009 1.13
6 Hypopituitarism after traumatic brain injury. Eur J Endocrinol 2005 1.08
7 Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocr Relat Cancer 2007 1.07
8 Virologic and immunologic evidence supporting an association between HHV-6 and Hashimoto's thyroiditis. PLoS Pathog 2012 1.06
9 Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma. Thyroid 2005 0.97
10 High prevalence of differentiated thyroid carcinoma in acromegaly. Clin Endocrinol (Oxf) 2005 0.97
11 Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. Endocr Relat Cancer 2010 0.97
12 Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism. J Clin Endocrinol Metab 2005 0.96
13 Regression of liver metastases of occult carcinoid tumor with slow release lanreotide therapy. World J Gastroenterol 2005 0.94
14 Activation of the somatotropic axis by testosterone in adult men: evidence for a role of hypothalamic growth hormone-releasing hormone. Neuroendocrinology 2003 0.94
15 A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization. Hum Mutat 2010 0.93
16 Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr Relat Cancer 2007 0.91
17 Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion. J Clin Endocrinol Metab 2003 0.90
18 Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. Endocr Relat Cancer 2007 0.89
19 Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid. J Clin Endocrinol Metab 2005 0.86
20 SRC homology-2-containing protein tyrosine phosphatase-1 restrains cell proliferation in human medullary thyroid carcinoma. Endocrinology 2005 0.85
21 Predictors of pituitary dysfunction in patients surviving ischemic stroke. J Clin Endocrinol Metab 2010 0.84
22 GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment. Clin Endocrinol (Oxf) 2008 0.83
23 Corticotropin releasing hormone: a diagnostic marker for behavioral and reproductive disorders? Front Biosci 2007 0.83
24 Protein kinase C: a putative new target for the control of human medullary thyroid carcinoma cell proliferation in vitro. Endocrinology 2012 0.83
25 Expression of functional KISS1 and KISS1R system is altered in human pituitary adenomas: evidence for apoptotic action of kisspeptin-10. Eur J Endocrinol 2010 0.82
26 MicroRNAs and possible role in pituitary adenoma. Semin Reprod Med 2008 0.81
27 Systemic illness. Pituitary 2008 0.80
28 Utilization of luminescent technology to develop a kinase assay: Cdk4 as a model system. J Pharm Biomed Anal 2005 0.79
29 In vitro testing of new somatostatin analogs on pituitary tumor cells. Mol Cell Endocrinol 2007 0.78
30 Antiproliferative effects of somatostatin analogs in pituitary adenomas. Pituitary 2006 0.77
31 Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly. Metabolism 2002 0.77
32 Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro. J Clin Endocrinol Metab 2004 0.77
33 Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism. Metabolism 2005 0.77
34 CYP11B2 -344T/C gene polymorphism and blood pressure in patients with acromegaly. J Clin Endocrinol Metab 2006 0.76
35 Plasma galanin response to head-up tilt in normal subjects and patients with recurrent vasovagal syncope. Metabolism 2003 0.75